CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Sam Whiting, M.D., Ph.D.
Calithera Biosciences, Inc
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
133 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Southern Highlands Private Hospital (cancer Centre)
Bowral, New South Wales, Australia
- Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
- Macquarie University Hospital
North Ryde, New South Wales, Australia
- Liverpool Hospital
Sydney, New South Wales, Australia
- Tweed Hospital
Tweed Heads, New South Wales, Australia
- Pindara Private Hospital
Benowa, Queensland, Australia
- Cairns Hospital
Cairns, Queensland, Australia
- Mater Misericordiae Limited - Division of Cancer Services
South Brisbane, Queensland, Australia
- Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
- Ballarat Health Services
Ballarat, Victoria, Australia
- Peninsula Private Hospital
Frankston, Victoria, Australia
- Cabrini Hospital
Malvern, Victoria, Australia
- Goulburn Valley Health
Shepparton, Victoria, Australia
- Hollywood Private Hospital
Nedlands, Western Australia, Australia
- Centre Hospitalier Régional Universitaire (chru) de Besançon - Jean-Minjoz
Besançon, France
- Chu de Bordeaux Hôpital Saint André
Bordeaux, France
- Centre François Baclesse
Caen, France
- Centre Jean Perrin
Clermont-Ferrand, France
- Centre Hospitalier Universitaire (chu) Henri-Mondor
Créteil, France
- Centre Georges-François Leclerc
Dijon, France
- Centre Léon Bérard
Lyon, France
- Institut Paoli-Calmettes Service D'Urologie
Marseille, France
- Institut de Cancérologie de Montpellier (icm)
Montpellier, France
- Centre Antoine Lacassagne
Nice, France
- Hôpital Européen Georges-Pompidou (hegp)
Paris, France
- Institut de Cancérologie de L'Ouest (ico) - Centre René Gauducheau
Saint-Herblain, France
- Chu de Strasbourg (les Hôpitaux Universitaires de Strasbourg)
Strasbourg, France
- Iucto Bureau Des Essais Cliniques (institut Claudius Regaud)
Toulouse, France
- Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
- Institut Gustave Roussy - Le Département de Medecine Oncologique
Villejuif, France
- Medical University Heidelberg, Nct (national Center for Tumour Diseases), Medical Oncology
Heidelberg, Baden-Wurttemberg, Germany
- Technischen Universitat München - Urologische Klinik
München, Bavaria, Germany
- Charité Universitätsmedizin Berlin, Dept. of Interdisciplinary Urology
Berlin, Germany
- Universitätsklinikum Carl Gustav Carus An Der Technischen Universität Dresden, Klinik Und Poliklinik
Dresden, Germany
- Universitätsklinikum Essen (aör) Westdeutsches Tumorzentrum
Essen, Germany
- Medizinische Hochschule Hannover
Hanover, Germany
- Universitätsklinikum Tübingen, Klinik Für Urologie
Tübingen, Germany
- Presidio Ospedaliero Antonio Perrino - U.O.C. Oncologia Medica
Brindisi, Italy
- S.C. Oncologia - Asst Cremona P.O. Ospedale Di Cremona
Cremona, Italy
- Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Apr 2018
- Primary completion
- 31 Aug 2020
- Completion
- 16 Jul 2021
- Last update posted
- 20 Mar 2023
- Registered enrollment
- 444
- Registry id
- NCT03428217
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.